Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies

The recently reported “UK variant” (B.1.1.7) of SARS-CoV-2 is thought to be more infectious than previously circulating strains as a result of several changes, including the N501Y mutation. We present a 2.9-Å resolution cryo-electron microscopy (cryo-EM) structure of the complex between the ACE2 receptor and N501Y spike protein ectodomains that shows Y501 inserted into a cavity at the binding interface near Y41 of ACE2. This additional interaction provides a structural explanation for the increased ACE2 affinity of the N501Y mutant, and likely contributes to its increased infectivity. However, this mutation does not result in large structural changes, enabling important neutralization epitopes to be retained in the spike receptor binding domain. We confirmed this through biophysical assays and by determining cryo-EM structures of spike protein ectodomains bound to 2 representative potent neutralizing antibody fragments.

[1]  William T. Harvey,et al.  Author Correction: Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies , 2021, Nature.

[2]  Shiho Tanaka,et al.  A recombinant ‘ACE2 Triple Decoy’ that traps and neutralizes SARS-CoV-2 shows enhanced affinity for highly transmissible SARS-CoV-2 variants , 2021, bioRxiv.

[3]  J. Lebbink,et al.  Experimental Evidence for Enhanced Receptor Binding by Rapidly Spreading SARS-CoV-2 Variants , 2021, bioRxiv.

[4]  Peng Zheng,et al.  Mutation N501Y in RBD of Spike Protein Strengthens the Interaction between COVID-19 and its Receptor ACE2 , 2021, bioRxiv.

[5]  P. Marrack,et al.  The basis of a more contagious 501Y.V1 variant of SARS-CoV-2 , 2021, Cell Research.

[6]  D. Ho,et al.  Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 , 2021, bioRxiv.

[7]  D. Ho,et al.  Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization , 2021, bioRxiv.

[8]  E. Hodcroft,et al.  Genetic Variants of SARS-CoV-2-What Do They Mean? , 2021, JAMA.

[9]  Carl A. B. Pearson,et al.  Estimated transmissibility and severity of novel SARS-CoV-2 Variant of Concern 202012/01 in England , 2020, medRxiv.

[10]  R. Friesner,et al.  Cryo-EM Structures of SARS-CoV-2 Spike without and with ACE2 Reveal a pH-Dependent Switch to Mediate Endosomal Positioning of Receptor-Binding Domains , 2020, Cell Host & Microbe.

[11]  Lisa E. Gralinski,et al.  Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection , 2020, Proceedings of the National Academy of Sciences.

[12]  Peter B Rosenthal,et al.  Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion , 2020, Nature.

[13]  X. Xie,et al.  Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy , 2020, Cell.

[14]  S. Subramaniam,et al.  High Potency of a Bivalent Human VH Domain in SARS-CoV-2 Animal Models , 2020, Cell.

[15]  Ralf Bartenschlager,et al.  Structures and distributions of SARS-CoV-2 spike proteins on intact virions , 2020, Nature.

[16]  Sarah K. Hilton,et al.  Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding , 2020, Cell.

[17]  A. Walls,et al.  Structure-guided covalent stabilization of coronavirus spike glycoprotein trimers in the closed conformation , 2020, Nature Structural & Molecular Biology.

[18]  Yan Li,et al.  Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy , 2020, Science.

[19]  I. Wilson,et al.  An alternative binding mode of IGHV3-53 antibodies to the SARS-CoV-2 receptor binding domain , 2020, bioRxiv.

[20]  Ilya J. Finkelstein,et al.  Structure-based design of prefusion-stabilized SARS-CoV-2 spikes , 2020, Science.

[21]  Mario J. Borgnia,et al.  Controlling the SARS-CoV-2 spike glycoprotein conformation , 2020, Nature Structural & Molecular Biology.

[22]  D. Burton,et al.  Structural basis of a shared antibody response to SARS-CoV-2 , 2020, Science.

[23]  William J. Liu,et al.  A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2 , 2020, Nature.

[24]  Shaun Rawson,et al.  Distinct conformational states of SARS-CoV-2 spike protein , 2020, Science.

[25]  Zhigang Wu,et al.  Molecular Architecture of the SARS-CoV-2 Virus , 2020, Cell.

[26]  Linqi Zhang,et al.  Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor , 2020, Nature.

[27]  K. Shi,et al.  Structural basis of receptor recognition by SARS-CoV-2 , 2020, Nature.

[28]  Qiang Zhou,et al.  Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2 , 2020, Science.

[29]  Young-Jun Park,et al.  Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.

[30]  B. Graham,et al.  Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation , 2020, Science.

[31]  S. Raunser,et al.  SPHIRE-crYOLO: A fast and well-centering automated particle picker for cryo-EM , 2018, bioRxiv.

[32]  Randy J Read,et al.  Real-space refinement in PHENIX for cryo-EM and crystallography , 2018, bioRxiv.

[33]  Conrad C. Huang,et al.  UCSF ChimeraX: Meeting modern challenges in visualization and analysis , 2018, Protein science : a publication of the Protein Society.

[34]  Muyuan Chen,et al.  High resolution single particle refinement in EMAN2.1. , 2016, Methods.

[35]  S. Scheres RELION: Implementation of a Bayesian approach to cryo-EM structure determination , 2012, Journal of structural biology.

[36]  B. Iverson,et al.  Rethinking the term “pi-stacking” , 2012 .

[37]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[38]  Karen N. Allen,et al.  research papers Acta Crystallographica Section D Biological , 2003 .

[39]  Bernhard Rupp,et al.  Correspondence e-mail: , 2000 .